Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | NP30179: Glofitamab monotherapy in R/R NHL

Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, provides updates from the Phase I/II NP30179 trial (NCT03075696) of single-agent glofitamab, a CD20xCD3 T-cell-engaging bispecific antibody, in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). In the dose-escalation trial, glofitamab produced durable responses, and further data are yet to be presented. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.